Original researchThe European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna
Cited by (0)
Contributors: All authors fulfill the criteria for authorship and have read and approved the final version of the manuscript.
Competing interests: GWP has received honoraria for lectures by Merck Serono, Amgen, Bayer, Servier, Lilly, Celgene, Roche and Sanofi Aventis; TF has received honoraria or research grants from MSD, Merck, BMS, Pfizer, Sandoz and Astra Zeneca; MP has received research support from Boehringer-Ingelheim, GlaxoSmithKline, Merck Sharp & Dome and Roche and honoraria for lectures, consultation or advisory board participation from Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche and Astra Zeneca; GJL has received research support from Pierre Fabre and honoraria for lectures, consultation or advisory board participation from Bristol-Myers Squibb and Roche; TB has received personal fees from Amgen (lecture fee and advisory board), personal fees from Bayer (lecture fee and advisory board), personal fees from Eisai (lecture fee and advisory board), personal fees from Eli Lilly (lecture fee and advisory board), personal fees from Novartis (lecture fee and advisory board), personal fees from PharmaMar (lecture fee) and personal fees from Roche (lecture fee) outside the submitted work. CCZ has received honoraria by Bristol Myers-Squibb, Merck Sharp Dohme, Novartis, Roche, Astra Zeneca, Ariad and Imugene. All remaining authors have declared no conflict of interest.
Provenance and peer review: Not commissioned; externally peer reviewed.